Pharmaceutical

Bayer has vested interest in survey results

A survey commissioned by Bayer Healthcare of 1,000 women aged 20 to 40 found that 39 percent had slept with a boyfriend by their third date. But many didn’t tell even their closest friends. As many as 11 percent slept with their most recent partner on the first date, and another 28 percent say they gave in to their sexual wantings by the second or third date. Despite all this intimacy, the poll also found that more than half of the women surveyed – 56 percent – say that the person they are sleeping with is not the person they are most comfortable discussing contraception with. Ten percent said that even discussing birth control with their doctors made them uneasy.

Bayer has an obvious vested interest in the outcome of that survey. The drug company makes one of the nation’s most popular oral contraceptives, Yaz. It is also known by the brand name Yasmin and the generic brand Ocella. Bayer has hit snags over the years marketing its blockbuster birth control pill.

First, the Food and Drug Administration (FDA) fined the drug maker and ordered they spend millions on a revamped advertising campaign after the agency deemed its Yaz commercials were misleading and were not being forthright about the drug’s life-threatening side effects.

Next came the lawsuits – an estimated 1,100 to date – from women who say they were not adequately warned of the dangers in taking Yaz. These women suffered from serious health problems including blood clots, heart attacks, kidney failure, gallbladder disease and seizures. Some complications resulted in death or disability.

Bayer’s response to the mounting lawsuits has been unwavering. The company contends it will “defend itself vigorously against these lawsuits.”

Source: Daily Record